NASDAQ:VIR
Vir Biotechnology, Inc. Stock News
$9.73
-0.200 (-2.01%)
At Close: May 17, 2024
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
01:41pm, Monday, 02'nd May 2022
Recently, Vir Biotechnology Inc (NASDAQ: VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:
Vir Biotechnology, Inc. (VIR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
03:10pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
12:39pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 –
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
01:02pm, Monday, 25'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
08:05pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
04:05pm, Thursday, 21'st Apr 2022
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter e
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
04:12pm, Monday, 18'th Apr 2022 Zacks Investment Research
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
08:02pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment community
3 Pharmaceutical Stocks With Awesome Futures
11:15am, Saturday, 09'th Apr 2022 The Motley Fool
The market is so pessimistic about anything COVID-related that everything has gotten super cheap.
3 Pharmaceutical Stocks With Awesome Futures
07:15am, Saturday, 09'th Apr 2022
The market is so pessimistic about anything COVID-related that everything has gotten super cheap.
The Zacks Analyst Blog Highlights Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals
03:32pm, Friday, 08'th Apr 2022 Zacks Investment Research
Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.
Antibody Treatments for COVD-19 Face Challenges in the U.S.
01:31pm, Friday, 08'th Apr 2022 Zacks Investment Research
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
Antibody Treatments for COVD-19 Face Challenges in the U.S.
10:32am, Friday, 08'th Apr 2022
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
